



**Amarantus**  
BioSciences

## **MEDIA CONTACTS:**

IR Sense  
Remy Barnarda  
[Remy@irsense.com](mailto:Remy@irsense.com)  
415.203.6386

## **Amarantus BioSciences to be Interviewed on The Big Biz Radio Show**

**SUNNYVALE, CA – January 12, 2012** – Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced the company will be a featured guest on The Big Biz Radio Show on Friday, January 13, 2012 at 1:10 PM PDT. The live broadcast can be accessed via the show's website: <http://bigbizshow.com/media/>

The Big Biz Show is a nationwide radio broadcast featuring commentators Bob Sullivan and Russ Nailz who discuss topics including current events, business trends, investment opportunities, innovations in headline making industries, and hot stock picks.

### **About Amarantus BioSciences, Inc.**

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit [www.amarantus.com](http://www.amarantus.com).

### **Forward Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those

identified under "Risk Factors" in Amaranthus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amaranthus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Amaranthus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.